繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 抗感染类 >> 药品目录 >> 抗生素类 >> 其它抗菌抗生素类 >> 多粘菌素B注射液(POLYMYXIN,POLYMYXIN B SULFATE)

多粘菌素B注射液(POLYMYXIN,POLYMYXIN B SULFATE)

2012-03-13 22:34:35  作者:新特药房  来源:中国新特药网天津分站  浏览次数:963  文字大小:【】【】【
简介: 部分中文多粘菌素B处方资料(仅供参考) 【药物名称】:多粘菌素B【英文名称】:polymyxinB【说 明】:注射用硫酸多粘菌素B:每瓶50mg(1mg=10000单位)。【功用作用】对绿脓杆菌、大肠杆菌、肺 ...

 部分中文多粘菌素B处方资料(仅供参考)
【药物名称】:多粘菌素B
【英文名称】:polymyxinB
【说       明】:注射用硫酸多粘菌素B:每瓶50mg(1mg=10000单位)。
【功用作用】对绿脓杆菌、大肠杆菌、肺炎克雷白杆菌,以及嗜血杆菌、肠杆菌属、沙门菌、志贺菌、百日咳杆菌、巴斯德菌和弧菌等革兰阴性菌有抗菌作用。
变形杆菌、奈瑟菌、沙雷菌、普鲁威登菌、革兰阴性菌和专性厌氧菌均对本类药物不敏感。细菌对本品与多粘菌素E之间有交叉耐药性,但对本类药物与他类抗菌药物间则没有交叉耐药性发现。
口服不吸收。注射后主要由尿排出,但在12小时内仅排出很少量,以后可达到20~100μg/ml浓度。停药以后1~3天内,继续有药物排泄。
【主要应用】绿脓杆菌及其他假单胞菌引起的创面、尿路以及眼、耳、气管等部位感染,也可用于败血症、腹膜炎。

Polymyxin B Injection
Dosage Form: injection, powder, for solution

Polymyxin B for Injection, USP
500,000 units
SAGENT™
Rx Only
To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

WARNING
CAUTION: WHEN THIS DRUG IS GIVEN INTRAMUSCULARLY AND/OR INTRATHECALLY, IT SHOULD BE GIVEN ONLY TO HOSPITALIZED PATIENTS, SO AS TO PROVIDE CONSTANT SUPERVISION BY A PHYSICIAN.
RENAL FUNCTION SHOULD BE CAREFULLY DETERMINED AND PATIENTS WITH RENAL DAMAGE AND NITROGEN RETENTION SHOULD HAVE REDUCED DOSAGE. PATIENTS WITH NEPHROTOXICITY DUE TO POLYMYXIN B SULFATE USUALLY SHOW ALBUMINURIA, CELLULAR CASTS, AND AZOTEMIA. DIMINISHING URINE OUTPUT AND A RISING BUN ARE INDICATIONS FOR DISCONTINUING THERAPY WITH THIS DRUG.
NEUROTOXIC REACTIONS MAY BE MANIFESTED BY IRRITABILITY, WEAKNESS, DROWSINESS, ATAXIA, PERIORAL PARESTHESIA, NUMBNESS OF THE EXTREMITIES, AND BLURRING OF VISION. THESE ARE USUALLY ASSOCIATED WITH HIGH SERUM LEVELS FOUND IN PATIENTS WITH IMPAIRED RENAL FUNCTION AND/OR NEPHROTOXICITY.
THE CONCURRENT OR SEQUENTIAL USE OF OTHER NEUROTOXIC AND/OR NEPHROTOXIC DRUGS WITH POLYMYXIN B SULFATE, PARTICULARLY BACITRACIN, STREPTOMYCIN, NEOMYCIN, KANAMYCIN, GENTAMICIN, TOBRAMYCIN, AMIKACIN, CEPHALORIDINE, PAROMOMYCIN, VIOMYCIN, AND COLISTIN SHOULD BE AVOIDED.
THE NEUROTOXICITY OF POLYMYXIN B SULFATE CAN RESULT IN RESPIRATORY PARALYSIS FROM NEUROMUSCULAR BLOCKADE, ESPECIALLY WHEN THE DRUG IS GIVEN SOON AFTER ANESTHESIA AND/OR MUSCLE RELAXANTS.
USAGE IN PREGNANCY: THE SAFETY OF THIS DRUG IN HUMAN PREGNANCY HAS NOT BEEN ESTABLISHED.

DESCRIPTION
Polymyxin B for Injection, USP is one of a group of basic polypeptide antibiotics derived from B polymyxa (B aerosporous). Polymyxin B sulfate is the sulfate salt of Polymyxins B1 and B2, which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillacea). The chemical name of polymyxin B sulfate is N - [4 - amino - 1 - [[1 - [[4 - amino - 1 - oxo - 1 - [[6,9,18 - tris(2 - aminoethyl) - 15 - benzyl - 3 - (1 - hydroxyethyl) - 12 - (2 - methylpropyl) - 2,5,8,11,14,17,20 - heptaoxo - 1,4,7,10,13,16,19 - heptazacyclotricos - 21 - yl]amino]butan - 2 - yl]amino] - 3 - hydroxy - 1 - oxobutan - 2 - yl]amino] - 1 - oxobutan - 2 - yl] - 6 - methyloctanamide; sulfuric acid. It has a potency of not less than 6000 polymyxin B units per mg, calculated on the anhydrous basis. The structural formulae are:

Each vial contains Polymyxin B Sulfate equivalent to 500,000 polymyxin B units for parenteral or ophthalmic administration.

Polymyxin B for Injection, USP is a white to almost white colored powder suitable for preparation of sterile solutions for intramuscular, intravenous drip, intrathecal, or ophthalmic use.

In the medical literature, dosages have frequently been given in terms of equivalent weights of pure polymyxin B base. Each milligram of pure polymyxin B base is equivalent to 10,000 units of polymyxin B and each microgram of pure polymyxin B base is equivalent to 10 units of polymyxin B.

Aqueous solutions of polymyxin B sulfate may be stored up to 12 months without significant loss of potency if kept under refrigeration. In the interest of safety, solutions for parenteral use should be stored under refrigeration and any unused portion should be discarded after 72 hours. Polymyxin B sulfate should not be stored in alkaline solutions since they are less stable.

CLINICAL PHARMACOLOGY

Polymyxin B sulfate has a bactericidal action against almost all gram-negative bacilli except the Proteus group. Polymyxins increase the permeability of bacterial cell wall membranes. All gram-positive bacteria, fungi, and the gram-negative cocci, N gonorrhoeae and N meningitidis, are resistant.

Polymyxin B has bactericidal action against almost all Gram-negative bacilli except the Proteus group. Polymyxins increase the permeability of the bacterial cell membrane leading to death of the cell. All Gram-positive bacteria, fungi, and Gram-negative cocci, are resistant to polymyxin B. Appropriate methods should be used when performing in vitro susceptibility testing of polymyxin B (1,2,3). The following in vitro susceptibility test criteria should only be used for interpreting the results of polymyxin B susceptibility testing against P. aeruginosa when the indicated quality control parameters are met during testing.

In vitro susceptibility test interpretive criteria for
polymyxin B sulfate against Pseudomonas aeruginosa
Minimal Inhibitory Concentration
(MIC) (mcg/mL)
Disk Diffusion Interpretive
Criteria (mm) (300 unit disk)
Pathogen Susceptible Intermediate Resistant Susceptible Intermediate Resistant
Pseudomonas
aeruginosa

≤2

4

≥8

≥12


≤11
In vitro susceptibility test quality control ranges for polymyxin B sulfate against
Pseudomonas aeruginosa

Quality Control Organism
(ATCC* Number)

Minimal Inhibitory Concentration (MIC) Range (mcg/mL)
Disk Diffusion
Quality Control Range (300 unit disk) (mm)
Pseudomonas aeruginosa
(27853)

1 - 4

14 - 18

Polymyxin B sulfate is not absorbed from the normal alimentary tract. Since the drug loses 50 percent of its activity in the presence of serum, active blood levels are low. Repeated injections may give a cumulative effect. Levels tend to be higher in infants and children. The drug is excreted slowly by the kidneys. Tissue diffusion is poor and the drug does not pass the blood brain barrier into the cerebrospinal fluid. In therapeutic dosage, polymyxin B sulfate causes some nephrotoxicity with tubule damage to a slight degree.

INDICATIONS AND USAGE

Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa.

Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa.

It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated:

H influenzae, specifically meningeal infections.

Escherichia coli, specifically urinary tract infections.

Aerobacter aerogenes, specifically bacteremia.

Klebsiella pneumoniae, specifically bacteremia.

NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

CONTRAINDICATIONS

This drug is contraindicated in persons with a prior history of hypersensitivity reactions to polymyxins.

WARNINGS

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Polymyxin B for Injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile and surgical evaluation should be instituted as clinically indicated.

PRECAUTIONS

General. Prescribing polymyxin B in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

See WARNING box.

Baseline renal function should be done prior to therapy, with frequent monitoring of renal function and blood levels of the drug during parenteral therapy.

Avoid concurrent use of a curariform muscle relaxant and other neurotoxic drugs (ether, tubocurarine, succinylcholine, gallamine, decamethonium and sodium citrate) which may precipitate respiratory depression. If signs of respiratory paralysis appear, respiration should be assisted as required, and the drug discontinued.

As with other antibiotics, use of this drug may result in overgrowth of nonsusceptible organisms, including fungi.

If superinfection occurs, appropriate therapy should be instituted.

Information for Patients. Patients should be counseled that antibacterial drugs including polymyxin B should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When polymyxin B is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by polymyxin B or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

Adverse Reactions

See WARNING box.

Nephrotoxic reactions: Albuminuria, cylinduria, azotemia, and rising blood levels without any increase in dosage.

Neurotoxic reactions: Facial flushing, dizziness progressing to ataxia, drowsiness, peripheral paresthesias (circumoral and stocking glove), apnea due to concurrent use of curariform muscle relaxants, other neurotoxic drugs or inadvertent overdosage, and signs of meningeal irritation with intrathecal administration, e.g., fever, headache, stiff neck and increased cell count and protein cerebrospinal fluid.

Other reactions occasionally reported: Drug fever, urticarial rash, pain (severe) at intramuscular injection sites, and thrombophlebitis at intravenous injection sites.

DOSAGE AND ADMINISTRATION

PARENTERAL:

Intravenous. Dissolve 500,000 polymyxin B units in 300 to 500 mL of 5% Dextrose Injection for continuous intravenous drip.

Adults and children. 15,000 to 25,000 units/kg body weight/day in individuals with normal kidney function. This amount should be reduced from 15,000 units/kg downward for individuals with kidney impairment. Infusions may be given every 12 hours; however, the total daily dose must not exceed 25,000 units/kg/day.

Infants. Infants with normal kidney function may receive up to 40,000 units/kg/day without adverse effects.

Intramuscular. Not recommended routinely because of severe pain at injection sites, particularly in infants and children. Dissolve 500,000 polymyxin B units in 2 mL sterile water for injection or 0.9% Sodium Chloride Injection or procaine hydrochloride injection 1%.

Adults and children. 25,000 to 30,000 units/kg/day. This should be reduced in the presence of renal impairment. The dosage may be divided and given at either 4 or 6 hour intervals.

Infants. Infants with normal kidney function may receive up to 40,000 units/kg/day without adverse effects.

Note: Doses as high as 45,000 units/kg/day have been used in limited clinical studies in treating prematures and newborn infants for sepsis caused by Ps aeruginosa.

Intrathecal. A treatment of choice for Ps aeruginosa meningitis. Dissolve 500,000 polymyxin B units in 10 mL 0.9% Sodium Chloride Injection for 50,000 units per mL dosage unit.

Adults and children over 2 years of age. Dosage is 50,000 units once daily intrathecally for 3 to 4 days, then 50,000 units once every other day for at least 2 weeks after cultures of the cerebrospinal fluid are negative and sugar content has returned to normal.

Children under 2 years of age. 20,000 units once daily, intrathecally for 3 to 4 days or 25,000 units once every other day. Continue with a dose of 25,000 units once every other day for at least 2 weeks after cultures of the cerebrospinal fluid are negative and sugar content has returned to normal.

IN THE INTEREST OF SAFETY, SOLUTIONS OF PARENTERAL USE SHOULD BE STORED UNDER REFRIGERATION, AND ANY UNUSED PORTIONS SHOULD BE DISCARDED AFTER 72 HOURS.

TOPICAL:

Ophthalmic. Dissolve 500,000 polymyxin B units in 20 to 50 mL sterile water for injection or 0.9% Sodium Chloride Injection for a 10,000 to 25,000 units per mL concentration.

For the treatment of Ps aeruginosa infections of the eye, a concentration of 0.1 percent to 0.25 percent (10,000 units to 25,000 units per mL) is administered 1 to 3 drops every hour, increasing the intervals as response indicates.

Subconjunctival injection of up to 100,000 units per day may be used for the treatment of Ps aeruginosa infections of the cornea and conjunctiva.

Note: Avoid total systemic and ophthalmic instillation over 25,000 units/kg/day.

HOW SUPPLIED

Each vial contains Polymyxin B Sulfate equivalent to 500,000 polymyxin B units and is supplied as follows:

NDC Polymyxin B for Injection, USP Package Factor
25021-117-10 500,000 units per vial 10 vials per carton

Storage Conditions

Before reconstitution: Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

Protect from light. Retain in carton until time of use.

After reconstitution: Product must be stored under refrigeration, between 2° and 8°C (36° and 46°F) and any unused portion should be discarded after 72 hours.

Sterile, Nonpyrogenic, Preservative-free.
The container closure is not made with natural rubber latex.

REFERENCES

  1. Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That Grow Aerobically; Approved Standard-8th edition. CLSI document M07-A8. CLSI, 940 West Valley Road, Suite 1400, Wayne, PA, 2009.
  2. CLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard-10th edition. CLSI document M02-A10, 2009.
  3. Clinical Laboratory and Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: 21st Informational Supplement. CLSI document M100-S21. CLSI, 940 West Valley Rd., Suite 1400, Wayne, PA 19087, 2011.

SAGENT™

Mfd. for SAGENT Pharmaceuticals
Schaumburg, IL 60195 (USA)
Made in India
©2011 Sagent Pharmaceuticals, Inc.

Revised: May 2011

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – VIAL LABEL

NDC 25021-117-10 Rx only

Polymyxin B for Injection, USP

500,000 units per vial

Each vial contains Polymyxin B Sulfate equivalent to 500,000 polymyxin B units

-----------------------------------------------------------------------
原产地英文商品名:
POLYMYXIN B SULFATE (500000U/VIAL 10VIALS/BOX)
原产地英文药品名:
POLYMYXIN B SULFATE
中文参考商品译名:
多粘菌素 B-50万单位/支 10支注射液/盒
中文参考药品译名:
多粘菌素 B
生产厂家中文参考译名:
Ben Venue Laboratories, Inc.
生产厂家英文名:
Ben Venue Laboratories, Inc.

责任编辑:admin


相关文章
DuoPlavin(阿司匹林/氯吡格雷复方片)
Evekeo(amphetamine sulfate tablets)
硫酸钡灌肠造影剂|BARI-ENEMA(Barium sulfate)
FDA批准PROAIR RESPICLICK吸入粉雾剂为哮喘新药
PROAIR RESPICLICK(硫酸沙丁胺醇吸入粉雾剂)
EVOTAZ(atazanavir/cobicistat)复方片
EVOTAZ(atazanavir and cobicistat tablets)
FDA批准复方抗艾药Evotaz用于治疗成人艾滋病
阿扎那韦胶囊Reyataz(atazanavir sulfate)
新型Reyataz(atazanavir oral powder)获FDA批准上市
硫酸长春地辛注射液|Fildesin(Vindesine Sulfate)
 

最新文章

更多

· VICCILLIN-S FOR INJECT...
· VICCILLIN-S COMBINATIO...
· Clarith(克拉霉素小児用...
· Flucloxacillin Solutio...
· 琥乙红霉素干混悬剂|E.E...
· ANAEMETRO Intravenous ...
· 利福昔明片|XIFAXANTA(R...
· Orbactiv(oritavancin)注...
· Sivextro(tedizolid 磷酸酯)
· ACETYLSPIRAMYCIN(乙酰螺...

推荐文章

更多

· VICCILLIN-S FOR INJECT...
· VICCILLIN-S COMBINATIO...
· Clarith(克拉霉素小児用...
· Flucloxacillin Solutio...
· 琥乙红霉素干混悬剂|E.E...
· ANAEMETRO Intravenous ...
· 利福昔明片|XIFAXANTA(R...
· Orbactiv(oritavancin)注...
· Sivextro(tedizolid 磷酸酯)
· ACETYLSPIRAMYCIN(乙酰螺...

热点文章

更多